Janssen will not be buying back the rights to a drug it shipped out to Provention Bio back in 2017 after it failed to move the needle in Crohn’s disease.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,